Kathleen Glick

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi et al. · Journal of Clinical Oncology · 2014 · 472 citations · Full text

Medicine, Oncology, Pediatrics +17

COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)

Janet Franklin, Todd A. Alonzo, Craig A. Hurwitz et al. · Blood · 2008 · 20 citations

Medicine, Oncology, Pediatrics +17

Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531

Alan S. Gamis, Richard Aplenc, Todd A. Alonzo et al. · Blood · 2013 · 14 citations

Medicine, Hematology, Oncology +17

Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.

Lillian Sung, Richard Aplenc, Todd A. Alonzo et al. · Blood · 2010 · 12 citations

Medicine, Oncology, Pediatrics +16

Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531

Alan S. Gamis, Todd A. Alonzo, Robert B. Gerbing et al. · Blood · 2010 · 12 citations

Medicine, Hematology, Oncology +17